Exactly. When a patient is in an open label trial that has standard of care vs SOC + another therapeutic the first thing they ask is what is the downside and more focused, what are the side effects. There are also questions about potential efficacy, etc.

I think many if not most will choose SOC plus the therapeutic if they think the side effects are manageable - and in the case of LL, that very much seems to be the case because it has proven itself over and over in trials.